Comparing the current results to its competitors, Edwards Lifesciences reported Revenue increase in the 2 quarter 2026 by 13.66 % year on year. The sales growth was above Edwards Lifesciences's competitors' average revenue growth of 9.82 %, achieved in the same quarter.
Edwards Lifesciences's Comment on Competition and Industry Peers
The company operates in the medical technology industry, which is characterized by intense competition from both divisions of larger corporations and smaller firms offering competitive products across various regions. It faces competition from established and emerging technologies and risks product obsolescence due to technological advancements and alternative therapies, including drug treatments. The company's strategy emphasizes developing safe and effective therapies supported by clinical studies and innovative features to improve patient outcomes and product performance. In the cardiovascular segment, the company identifies itself as a leading global competitor. Its primary competitors in Transcatheter Aortic Valve Replacement (TAVR) are Medtronic plc and Abbott Laboratories. In Transcatheter Mitral and Tricuspid Therapies (TMTT), Abbott Laboratories is the main competitor, alongside numerous other companies. In the surgical products category, Medtronic plc and Abbott Laboratories are the primary competitors.
November 25, 2024
In the intricate world of cardiac intervention, where every heartbeat matters, Edwards Lifesciences stands at the forefront of medical innovation with its SAPIEN 3 Ultra RESILIA valve. Recently showcased at the prestigious PCR London Valves 2024 conference and highlighted in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions, the valve has proven itself a beacon of hope for thousands of patients. The latest real-world data, extracted from an extensive analysis of over 9,000 propensity-matched patients in the STS/ACC TVT Registry, demonstrates not just durability but an impressive commitment to patient outcomes in a landscape rife with uncertainty.What sets the SAPIEN 3 Ult...
August 31, 2024
In a historic first for cardiovascular medicine, the all-female transcatheter aortic valve implantation (TAVI) trial has demonstrated excellent outcomes for patients using Edwards Lifesciences Corporation s valves. This groundbreaking study, focusing solely on women, marks a significant step forward in understanding and addressing gender-specific health issues in cardiac care. Despite the promising clinical results, Edwards Lifesciences financial performance in the second quarter of 2024 exhibits a mixed picture.Edwards Lifesciences Corporation reported a return on assets (ROA) of 16.12% for the second quarter of 2024, a decline from its average ROA of 16.47%. This dip in returns comes despite a net income ...
June 3, 2024
Edwards Lifesciences Sells Critical Care Unit to BD in $4.2 Billion Deal: Focus Shifts to Strategic GrowthEdwards Lifesciences, a leading medical technology company, has announced that it will sell its Critical Care product group to Becton, Dickinson and Company (BD) in an all-cash transaction valued at $4.2 billion. This deal marks a shift in Edwards strategy, as it abandons plans for a spin-off and redirects its focus towards funding strategic growth investments.The sale of the Critical Care unit enhances Edwards balance sheet flexibility and allows the company to leverage the after-tax cash proceeds for future expansion. By divesting this division to BD, Edwards can streamline its operations and concent...
March 11, 2024
Edwards Lifesciences, a leading medical device company, has announced the promising results from two large, real-world studies conducted using TVT Registry data. The studies highlight the continued success of patients treated with the Edwards SAPIEN valve platform. Notably, the latest SAPIEN 3 Ultra RESILIA valve demonstrated lower rates of complications and improved patient outcomes. Additionally, Edwards Lifesciences reported a significant revenue increase in the fourth quarter of 2023, outperforming its competitors. This article will outline these facts and evaluate their impact on the company.Edwards Lifesciences has once again demonstrated its commitment to delivering exceptional patient outcomes with i...
February 2, 2024
In a breakthrough announcement, Edwards Lifesciences Corporation has received U.S. Food and Drug Administration (FDA) approval for its EVOQUE tricuspid valve replacement system. This cutting-edge transcatheter therapy marks a significant milestone as the first of its kind for treating tricuspid regurgitation (TR), a condition characterized by the backflow of blood from the right ventricle to the right atrium, leading to severe health issues. Let s delve into the details of this groundbreaking approval, alongside assessing the impact it had on Edwards Lifesciences as a company.The EVOQUE Valve Replacement System:The EVOQUE system is a revolutionary transcatheter therapy designed to improve the health status o...
December 7, 2023
Edwards Lifesciences Outlines Growth Strategy and Technology Pipeline at Investor Conference Edwards Lifesciences Corporation, a leading medical technology company, recently held its annual investor conference where it unveiled its sharpened focus and growth strategy for the future. The conference also provided an update on the company s technology pipeline and shared financial guidance. One of the key highlights of the conference was the expectation of an early completion of enrollment in the PROGRESS study. This study focuses on moderate aortic stenosis (AS) patients and is expected to be completed by early 2024. Additionally, data from the EARLY TAVR study, targeting severe asymptomatic AS patient...
Publicly Traded Peers of Edwards Lifesciences Corporation
Boston Scientific Corporation Share Performance
-55.42%
One Year
Boston Scientific Corporation
Profile
Boston Scientific Corporations business model centers on creating innovative medical devices for diverse specialties, aimed at addressing unmet medical needs and enhancing patient outcomes. The company sells its products to healthcare professionals and hospitals globally, supported by robust sales and distribution networks. It prioritizes research and development to continually introduce new technologies and solutions.
Lemaitre Vascular Inc is a medical device company specializing in the design, development, and distribution of innovative medical devices for the treatment of peripheral vascular disease. Their business model revolves around creating and manufacturing high-quality products that address specific needs in the field of vascular surgery. They leverage a combination of direct sales, distribution partnerships, and ongoing research and development efforts to effectively reach healthcare professionals and provide comprehensive solutions for patients.
Lucid Diagnostics Inc is a healthcare company that operates with a business model focused on developing and providing innovative diagnostic solutions for the early detection and prevention of diseases, aimed at improving patient outcomes and reducing healthcare costs. They leverage advanced technologies and medical expertise to deliver accurate and reliable diagnostic services to healthcare providers, enabling better decision-making and personalized treatment plans for patients.
Masimo Corp is a medical technology company that focuses on developing and manufacturing innovative monitoring devices for patient care. Their business model revolves around creating and selling advanced noninvasive monitoring solutions to healthcare providers worldwide. They also generate revenue through licensing agreements, providing maintenance and support services, and selling disposable products and accessories related to their monitoring devices.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Sources:
Edwards Lifesciences Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Edwards Lifesciences Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
